A year after stunning China OK, Shanghai Alzheimer's drugmaker set to enroll first US patient — and the stakes are huge
Just as experts are set to debate whether Biogen’s aducanumab should become the first Alzheimer’s drug to be approved in the US in almost two decades, a therapy that seized a conditional OK in China late last year — shocking scientists around the world — is finally making headway in the clinic.
The US arm of Shanghai Green Valley’s global Phase III trial has identified its first patient, Bloomberg reported, and dosing will begin in four weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
